{"success":true,"type":"rich","version":"1.0","cache_age":86400,"width":440,"height":500,"provider_name":"RiffReporter","provider_url":"https:\/\/www.riffreporter.de","safety":"nonadult","asset_type":"article","url":"https:\/\/www.riffreporter.de\/de\/wissen\/bc007-berlincures-longcovid-mecfs-erlangen-studie-medikament","category":"Wissen","author_name":"Martin R\u00fccker","author_url":"https:\/\/www.riffreporter.de\/de\/autorinnen-und-autoren\/martin-ruecker","title":"Long-Covid-Hoffnung: Woran BC 007 (vorerst) scheiterte","summary":"Viele Long-Covid- und ME\/CFS-Patienten setzten gro\u00dfe Erwartungen in das Medikament BC 007 eines Berliner Start-Ups. Nun scheiterte es \u2013 doch woran eigentlich?","publication_date":"07.12.2024","thumbnail_url":"https:\/\/riff.media\/images\/bc007-longcovid-corona-mecfs-medikament.png?w=440&h=247&fit=crop-42-42&s=b14f65892a73c0d380da95d43b119f60","thumbnail_width":440,"thumbnail_height":247,"thumbnail_credit":null,"thumbnail_credit_url":null,"thumbnail_credit_note":null,"html":"